RxDoctor Payments Data

John Peterson, MD

Hematology & Oncology · Hickory, NCNPI 1417957234

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 99.4% of the total across 554 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 60 manufacturers, the largest accounting for just 9.2% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2020 at $2,292 and has fallen 76.6% since, to $537 in 2025.

$9,273in general payments, 2019–2025

Across 554 payments — averaging $16.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$853
  • Novartis$559
  • Merck$530
  • Johnson & Johnson$521
  • Amgen$472
  • Pfizer$438
  • plus $6K from 54 others

What the payments were for

  • Food & beverage$9,21499%
  • Education$591%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$9,273 in reported general payments places this provider in the 75th percentile of 358 hematology & oncology providers in North Carolina.

See all hematology & oncology providers in North Carolina →

Medicare billing

Part B allowed, 2024
$895,588
Medicare patients
443
Services billed
34,890

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Tamoxifen Citrate12$303

Paid to pharmacies, not to this prescriber.

Other hematology & oncology in Hickory

See the full list for North Carolina →

Where these figures come from

Is this you, or does something look wrong? →